Clinical and pathological characteristics of the patients with newly diagnosed DLBCL
| Characteristic . | IPI risk group . | P value . | |||
|---|---|---|---|---|---|
| Low (n = 1229) . | Low-intermediate (n = 521) . | High-intermediate (n = 493) . | High (n = 349) . | ||
| Sex | .116 | ||||
| Male | 654 (53.2) | 281 (53.9) | 277 (56.2) | 200 (57.3) | |
| Female | 575 (46.8) | 240 (46.1) | 216 (43.8) | 149 (42.7) | |
| Age, y | < .0001 | ||||
| ≤60 | 913 (74.3) | 262 (50.3) | 229 (46.5) | 49 (14.0) | |
| >60 | 316 (25.7) | 259 (49.7) | 264 (53.5) | 300 (86.0) | |
| Ann Arbor stage | < .0001 | ||||
| Ⅰ-Ⅱ | 1062 (86.4) | 185 (35.5) | 43 (8.7) | 4 (1.1) | |
| Ⅲ-Ⅳ | 167 (13.6) | 336 (64.5) | 450 (91.3) | 345 (98.9) | |
| Extranodal involvement | < .0001 | ||||
| 0-1 | 1206 (98.1) | 426 (81.8) | 229 (46.5) | 52 (14.9) | |
| ≥2 | 23 (1.9) | 95 (18.2) | 264 (53.5) | 297 (85.1) | |
| Serum LDH | < .0001 | ||||
| Normal | 1049 (85.4) | 212 (40.7) | 85 (17.2) | 16 (4.6) | |
| >1 × ULN | 180 (14.6) | 309 (59.3) | 408 (82.8) | 333 (95.4) | |
| ECOG performance status | < .0001 | ||||
| 0-1 | 1212 (98.6) | 478 (91.7) | 400 (81.1) | 158 (45.3) | |
| ≥ 2 | 17 (1.4) | 43 (8.3) | 93 (18.9) | 191 (54.7) | |
| Cell of origin (Han) | < .0001 | ||||
| GCB | 431/1016 (42.4) | 162/404 (40.1) | 131/390 (33.6) | 100/307 (32.6) | |
| non-GCB | 585/1016 (57.6) | 242/404 (59.9) | 259/390 (66.4) | 207/307 (67.4) | |
| BCL2/MYC double expressor | < .0001 | ||||
| Yes | 161/782 (20.6) | 80/281 (28.5) | 76/275 (27.6) | 79/216 (36.6) | |
| No | 621/782 (79.4) | 201/281 (71.5) | 199/275 (72.4) | 137/216 (63.4) | |
| BCL2 and MYC translocation | .057 (Fisher) | ||||
| Yes | 11/623 (1.8) | 4/246 (1.6) | 2/251 (0.8) | 9/201 (4.5) | |
| No | 612/623 (98.2) | 242/246 (98.4) | 249/251 (99.2) | 192/201 (95.5) | |
| Characteristic . | IPI risk group . | P value . | |||
|---|---|---|---|---|---|
| Low (n = 1229) . | Low-intermediate (n = 521) . | High-intermediate (n = 493) . | High (n = 349) . | ||
| Sex | .116 | ||||
| Male | 654 (53.2) | 281 (53.9) | 277 (56.2) | 200 (57.3) | |
| Female | 575 (46.8) | 240 (46.1) | 216 (43.8) | 149 (42.7) | |
| Age, y | < .0001 | ||||
| ≤60 | 913 (74.3) | 262 (50.3) | 229 (46.5) | 49 (14.0) | |
| >60 | 316 (25.7) | 259 (49.7) | 264 (53.5) | 300 (86.0) | |
| Ann Arbor stage | < .0001 | ||||
| Ⅰ-Ⅱ | 1062 (86.4) | 185 (35.5) | 43 (8.7) | 4 (1.1) | |
| Ⅲ-Ⅳ | 167 (13.6) | 336 (64.5) | 450 (91.3) | 345 (98.9) | |
| Extranodal involvement | < .0001 | ||||
| 0-1 | 1206 (98.1) | 426 (81.8) | 229 (46.5) | 52 (14.9) | |
| ≥2 | 23 (1.9) | 95 (18.2) | 264 (53.5) | 297 (85.1) | |
| Serum LDH | < .0001 | ||||
| Normal | 1049 (85.4) | 212 (40.7) | 85 (17.2) | 16 (4.6) | |
| >1 × ULN | 180 (14.6) | 309 (59.3) | 408 (82.8) | 333 (95.4) | |
| ECOG performance status | < .0001 | ||||
| 0-1 | 1212 (98.6) | 478 (91.7) | 400 (81.1) | 158 (45.3) | |
| ≥ 2 | 17 (1.4) | 43 (8.3) | 93 (18.9) | 191 (54.7) | |
| Cell of origin (Han) | < .0001 | ||||
| GCB | 431/1016 (42.4) | 162/404 (40.1) | 131/390 (33.6) | 100/307 (32.6) | |
| non-GCB | 585/1016 (57.6) | 242/404 (59.9) | 259/390 (66.4) | 207/307 (67.4) | |
| BCL2/MYC double expressor | < .0001 | ||||
| Yes | 161/782 (20.6) | 80/281 (28.5) | 76/275 (27.6) | 79/216 (36.6) | |
| No | 621/782 (79.4) | 201/281 (71.5) | 199/275 (72.4) | 137/216 (63.4) | |
| BCL2 and MYC translocation | .057 (Fisher) | ||||
| Yes | 11/623 (1.8) | 4/246 (1.6) | 2/251 (0.8) | 9/201 (4.5) | |
| No | 612/623 (98.2) | 242/246 (98.4) | 249/251 (99.2) | 192/201 (95.5) | |
N = 2592; unless otherwise indicated, data are n (%).
ENI, extra-nodal involvements; ULN, upper limit of normal.